Metraipolis › archive › dc_fa34fe0b9240

Dual targeting of joint and lung disease: efficacy of tofacitinib plus iguratimod combination in progressive fibrosing rheumatoid arthritis-associated… — Europe PMC PMID:41624877

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/41624877
DOI: 10.3389/fimmu.2025.1624125
License (as archived): solo-consultazione
Archived: 2026-11-06T18:10:04.254Z
SHA-256 of the archived text: d61b7de9ce7042d24bed7e393569284961e2af778cc3c18a2c7f8ea69656814a
Stable URL of this page: https://metraipolis.com/documento/dc_fa34fe0b9240

How to cite

Dual targeting of joint and lung disease: efficacy of tofacitinib plus iguratimod combination in progressive fibrosing rheumatoid arthritis-associated… — Europe PMC PMID:41624877 — Europe PMC (en), https://europepmc.org/article/MED/41624877 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_fa34fe0b9240 (Metraipolis archive dc_fa34fe0b9240, sha256 d61b7de9ce7042d24bed7e393569284961e2af778cc3c18a2c7f8ea69656814a)

BibTeX

@misc{dcfa34fe0b9240,
  title = {Dual targeting of joint and lung disease: efficacy of tofacitinib plus iguratimod combination in progressive fibrosing rheumatoid arthritis-associated… — Europe PMC PMID:41624877},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41624877},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_fa34fe0b9240; sha256 d61b7de9ce7042d24bed7e393569284961e2af778cc3c18a2c7f8ea69656814a},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41624877. Agents can read the archived copy with the MCP tool read_document.